Independent Editorial Rankings
We independently rank GLP-1 telehealth providers, weight loss programs, and the pharmacies behind them — so you can save money without falling for sketchy ads.
Reader-supported. When you sign up with a provider through our links we may earn a commission at no extra cost to you. How we make money.
Why readers use us
Brand-name Wegovy retails for around $1,349/month without insurance. The median compounded semaglutide provider in our dataset charges $175/month— same active ingredient, same weekly injection, a fraction of the cost.
Cheapest first-month rate currently in our dataset: $0/mo. Introductory pricing varies by provider and typically increases after the first month — always verify on the provider's site before signing up.
Quick Match
Three questions. We'll instantly show you the highest-rated provider that matches your budget, state, and preference — based on real pricing data.
Featured Partners
Best for mainstream telehealth GLP-1 access
“Both semaglutide and tirzepatide available”
Best for lab-monitored compounded GLP-1 with mandatory video visit
Best for patients who want the option to switch between compounded and brand-name GLP-1 through one provider
Every provider in our dataset has a first-party editorial review with a six-dimension score, verified pricing, state coverage, and primary-source citations. Read what we found before signing up.
Use our savings calculator to see what you could pay — then compare providers side by side to find the best deal.
Interactive pharmacokinetic simulator showing how semaglutide, tirzepatide, and Foundayo (orforglipron) build up across the standard FDA titration schedule.
6-drug interactive timeline showing when nausea peaks, when it resolves, and what every other GLP-1 side effect looks like by week. Every cell anchored to a primary source.
Coverage Map
Click any state to see the providers that ship and prescribe there. Darker squares mean more provider options available.
Coverage data compiled from 539 GLP-1 telehealth providers tracked by Weight Loss Rankings.
Editorial flagship
Primary-source deep-dives on GLP-1 weight-loss medications, every claim cited from FDA prescribing information and PubMed.
Which GLP-1 telehealth providers actually let you cancel anytime — versus lock you into a membership, multi-month prepay, or contract. Cancellation, commitment, and refund terms compared across the providers we track, with a downloadable dataset.
Read the analysis→State-by-state dataset of GLP-1 and medical weight-loss care access: 31,083 NPI-verified obesity-medicine, endocrinology, and bariatric clinics, clinics per 100,000 residents, verified telehealth coverage, the cheapest verified compounded semaglutide and tirzepatide price in every state, and a Care Gap Index comparing each state's adult obesity prevalence (CDC BRFSS 2024) to its specialist supply.
Read the analysis→Quarterly tracker of Medicaid GLP-1 spending and prescriptions in every state, from the CMS State Drug Utilization Data. US Medicaid spent about $8.8 billion (gross, before rebates) on GLP-1s in 2024; Wegovy's national spend rose from $1.43 billion in 2024 to $2.60 billion in 2025 and Zepbound's jumped 6.3×. When Pennsylvania ended obesity-drug coverage on January 1, 2026, quarterly Wegovy prescriptions fell 96%. Full downloadable dataset inside.
Read the analysis→A clinician-informed 7-day plan, protein & fiber targets, food lists, and a grocery list — sent straight to your inbox.